Baycol Withdrawal Gives Boost To Pravachol; Will Crestor NDA Be Affected?
Executive Summary
Bristol-Myers Squibb's Pravachol is gaining share in the retail market in the early days following the withdrawal of Bayer's Baycol, prescription tracking data from ArcLight indicate.
You may also be interested in...
Blast From the Past: “Pay for Delay” and the Blockbuster Patent Settlement
The Supreme Court wades into the competitive impact of so-called pay-for-delay settlements, while AstraZeneca and Actavis agree on the end of Crestor’s exclusivity period. Those developments are important – but not nearly as much as they used to be.
COX-2 Backlash? Fewer First-Cycle Approvals Would Signal Tougher FDA
A first-cycle drug approval rate significantly lower than 40% could provide the first sign of an effect of COX-2 inhibitor safety issues on FDA reviews, a report from the contract research organization Parexel states
COX-2 Backlash? Fewer First-Cycle Approvals Would Signal Tougher FDA
A first-cycle drug approval rate significantly lower than 40% could provide the first sign of an effect of COX-2 inhibitor safety issues on FDA reviews, a report from the contract research organization Parexel states